Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients.

ABSTRACT:

Objective

To evaluate the efficacy and safety of apalutamide prostate cancer compared to the pivotal trials patients and to identify the first subsequent therapy in a real-world setting.

Methods

The study is prospective and observational based on real-world evidence, performed by different medical disciplines and eight academics centres around Barcelona, Spain. It included all patients with metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide from June 2018 to December 2022.

Results

Of 227 patients treated with apalutamide, 10% had ECOG-PS 2, and 41% were diagnosed with new-generation imaging. In the mHSPC group (209 patients), 75 years was the median age, 53% had synch

SUBMITTER: Sanchez JC 

PROVIDER: S-EPMC10757138 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature